NAD+ and Peptide Longevity Stacks: GHK-Cu, BPC-157, Epitalon Protocols (2026 Research Review)

Last updated May 28, 2026 ·
Medically reviewed by Dr. Marcus Tan, MD ·
~13 min read ·
Research-compound disclaimer below

The most-cited 2026 longevity protocols pair NAD+ precursors (NMN 250–500 mg/day or subcutaneous NAD+ 50–100 mg 2×/week) with cycled research peptides on non-overlapping pathways: GHK-Cu for collagen and copper-dependent repair, Epitalon pulse-dosed (10 days on / 20 days off) for telomere biology, and BPC-157 cycled 6–8 weeks for vascular and gut repair. Stacking more than three compounds simultaneously is not recommended due to attribution loss — researchers cannot identify which compound is producing which effect.

Why stack NAD+ with peptides? (the non-overlapping pathways argument)

The intellectually honest case for stacking NAD+ with research peptides is not “more is better.” It is that the four compounds most often discussed — NAD+ precursors, GHK-Cu, BPC-157, and Epitalon — address different biological systems with limited overlap. NAD+ is a coenzyme central to cellular energy metabolism and a substrate for the sirtuin family of repair enzymes. GHK-Cu is a copper-binding tripeptide that participates in collagen synthesis and copper-dependent enzymatic activity. BPC-157 is a gut-derived peptide with preclinical evidence for vascular endothelial growth and tissue repair. Epitalon is a synthetic tetrapeptide studied for its effects on telomerase activity and pineal-axis regulation.

Because each compound enters the body through a different mechanistic door, stacking can — in theory — produce additive effects without the redundancy you see in, say, a stack of three different NAD+ precursors. The same logic argues against piling on more compounds: once you exceed three concurrent agents, attribution collapses, and a researcher (or a careful self-experimenter) cannot tell which compound is producing which outcome.

The 2024–2026 longevity literature has not produced a single randomized trial of the full stack in humans. What exists is mechanistic plausibility, individual-compound research (most of it preclinical), and a body of user-reported protocols on longevity forums and clinic websites. We treat that as a signal of interest, not as clinical proof.

The foundation: NAD+ precursor dosing for longevity

NAD+ is the foundation because its evidence base is the strongest of the four compounds and because oral precursors and subcutaneous NAD+ have a clearer regulatory and clinical track record than the peptides. Most longevity-focused protocols treat NAD+ as the continuous “baseline” layer and cycle peptides on top of it.

Oral NMN — research dose ranges from 2024–2026

Nicotinamide mononucleotide (NMN) is the precursor most associated with David Sinclair’s lab and a string of 2024–2025 randomized controlled trials in older adults. The research dose range cited in those trials is 250–500 mg/day, taken orally, typically in the morning. Higher doses have been tested without obvious safety signals but without demonstrating proportionally greater benefit on the primary endpoints (walking distance, blood NAD+ levels, insulin sensitivity in some sub-analyses).

The regulatory status of NMN remains in flux in the United States; the FDA has flagged NMN’s eligibility as a dietary supplement, but it continues to be sold widely. Treat the dosing range as research-derived, not as a labeled directive.

Oral NR — what the Brenner lab and long-COVID RCT showed

Nicotinamide riboside (NR) is the precursor with the largest published RCT base, associated with Charles Brenner’s lab and the ChromaDex Niagen product family. Research doses range from 300 mg to 1,000 mg/day. A 2023 long-COVID trial and earlier work in older adults established a clean safety profile and consistent elevation of whole-blood NAD+, with mixed signals on functional outcomes. We cover NR vs NMN trade-offs in more detail in our NMN vs NR comparison.

Subcutaneous NAD+ — when injection makes sense over oral

Subcutaneous NAD+ at 50–100 mg, 1–2×/week, is the compounded protocol most commonly prescribed by longevity telehealth. It is favored when oral precursor response has plateaued, when gut absorption is impaired, or when a patient wants more direct loading of the NAD+ pool. IV NAD+ — 500–1,000 mg per session, roughly monthly — is the highest-dose option and the most resource-intensive; we cover it in detail in our IV NAD+ therapy guide. For a side-by-side of oral vs subQ vs IV economics, see our NAD+ therapy cost calculator and our breakdown of NAD+ bioavailability by delivery method.

GHK-Cu: the copper-binding tripeptide

GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a sequence that occurs endogenously in human plasma and declines with age. Its two best-characterized roles are as a copper-delivery vehicle to copper-dependent enzymes and as a signal for collagen synthesis in dermal fibroblasts. It is the peptide with the longest cosmetic-industry track record and the shortest list of approved injectable indications — namely, none.

Topical vs subcutaneous — what is regulated as what

Topical GHK-Cu at 1–2% concentrations appears in serums, scalp formulations, and post-procedure creams. These are regulated as cosmetics in the United States, not as drugs, and are broadly legal to sell and to use. Subcutaneous injectable GHK-Cu is a different category: it is sold by research-chemical vendors as “not for human use,” is not FDA-approved for any clinical indication, and is treated as a research compound. The two product categories should not be conflated.

Research cycling protocols

The dose range described in the research-protocol literature and reported in clinic practice is 1–5 mg per injection, 2–3×/week, run for 6–8 weeks on, 4 weeks off. The rationale for cycling is twofold: copper-dependent pathways saturate quickly, and there is no human evidence supporting indefinite continuous use. Cycling also makes attribution easier when running GHK-Cu alongside NAD+.

What the evidence actually shows (and does not)

The published evidence for GHK-Cu is predominantly in vitro and in animal models, with consistent signals for collagen upregulation, wound healing, and gene-expression modulation. There are no large human RCTs of systemic injectable GHK-Cu for longevity endpoints. Reported user benefits — skin texture, hair density, recovery from soft-tissue injury — are plausible mechanistically but not proven at the level a regulator would require for a labeled indication.

BPC-157: the gut-derived “body protection” peptide

BPC-157 is a 15-amino-acid sequence isolated from a larger protein found in human gastric juice. The name — Body Protection Compound — reflects its preclinical reputation for accelerating tissue repair across multiple organ systems. It is the most-discussed research peptide in athletic-recovery and gut-health protocols. It is also not FDA-approved for any clinical indication.

Vascular and tissue-repair research

The preclinical literature on BPC-157 is unusually broad: rodent studies report effects on vascular endothelial growth factor (VEGF) expression, gut mucosal healing, tendon and ligament regeneration after injury, and recovery from chemical and mechanical insults. Human RCT data remain limited. The mechanistic story — that BPC-157 promotes angiogenesis at sites of damage — is biologically coherent, but the leap from rodent injury models to human longevity programs is large.

WADA banned — what athletes need to know

The World Anti-Doping Agency added BPC-157 to its prohibited list, citing its potential performance and recovery effects. Any athlete subject to in-competition or out-of-competition testing should treat BPC-157 as a banned substance regardless of its FDA status. This is a genuine constraint for collegiate, Olympic, professional, and many masters-level competitors.

Cycling protocols from the published research

The most commonly reported research dose is 250–500 mcg, 1–2×/day, subcutaneously, run for 6–8 weeks followed by a 4-week washout. Some protocols describe oral administration for gut-specific indications; the bioavailability and clinical equivalence of oral BPC-157 have not been established to a regulator’s standard.

Epitalon: the telomere peptide with the longest controversy

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide — alanine-glutamic acid-aspartic acid-glycine — derived from epithalamin, an extract of the pineal gland. It is the longevity research peptide most directly associated with telomere biology, and it carries the longest and most contested evidence trail of the three compounds discussed here.

The Khavinson Russian longevity data

Most of the primary human data on Epitalon comes from the laboratory of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, beginning in the 1980s. The cited trials report increased lifespan in elderly cohorts, normalization of melatonin rhythms, and biomarker improvements. These remain the principal data points cited in 2026 protocol literature.

Why replication has been limited outside Russia

The Khavinson body of work has not been replicated at scale by independent Western laboratories. Methodological details, randomization procedures, and primary data availability have been points of skepticism in Western longevity reviews. None of this means the underlying biology is wrong; it means the evidence base does not yet meet the standard most regulators or peer reviewers in the US and EU would require to support a labeled clinical indication.

Pulse-dosed protocols (10 on / 20 off)

The Epitalon dose range described in the research-protocol literature is 5–10 mg per injection, administered subcutaneously. The most commonly reported cycling structure is 10 consecutive days on, then 20 days off, or a maintenance variant of 10 days once per quarter. Pulse dosing — rather than continuous administration — is the structural choice that distinguishes Epitalon protocols from GHK-Cu and BPC-157 cycling and reflects the original Russian trial designs.

The non-overlapping-pathways framework (why this stack actually makes sense)

The strongest argument for the NAD+ + GHK-Cu + BPC-157 + Epitalon stack is mechanistic separation. NAD+ acts on cellular energy metabolism and sirtuin-driven repair. GHK-Cu acts on collagen biology and copper-dependent enzymes. BPC-157 acts on vascular and mucosal repair. Epitalon acts on telomere and pineal-axis biology. There is no obvious site of redundancy, which means stack effects, if real, would be additive rather than overlapping.

Contrast that with a stack of three NAD+ precursors (NMN + NR + NAD-IV), or a stack of three growth-factor peptides, where the compounds are pushing the same lever and the marginal benefit of the third addition is unclear. The non-overlapping principle is the only architectural justification we find persuasive for running this many research compounds at once — and it only holds if cycling is disciplined.

The 3-compound maximum rule (and why everyone breaks it)

The single most-broken rule in the consumer longevity-stack space is the three-compound limit. Sales pages and forum protocols routinely describe stacks of five, seven, even ten compounds run concurrently. The honest research-protocol position is that when more than three compounds are active at the same time, you lose attribution: if you feel better (or worse), you cannot tell which compound is responsible.

The conservative implementation is to run NAD+ continuously as the baseline, and to layer one peptide at a time on its own cycle. That structure preserves attribution, lets you isolate side effects, and avoids overloading a metabolic profile that has not been studied in the relevant combination. Smart cycling beats large stacks, particularly when the underlying evidence base is preclinical and the compounds are not FDA-approved.

A sample 90-day research-protocol calendar

The calendar below is provided as an educational illustration of how the principles above — one peptide at a time, non-overlapping pathways, disciplined cycling, NAD+ as the continuous baseline — could be sequenced over roughly 18 weeks. It is not a prescription, and it should be reviewed against your medical history with a licensed prescriber before any of the steps below are considered.

Weeks 1–6: NAD+ + GHK-Cu (collagen and recovery focus)

Begin with NAD+ as the continuous baseline (oral NMN 250–500 mg/day, or subQ NAD+ 50–100 mg twice weekly, per your prescriber). Layer GHK-Cu at 1–5 mg subcutaneously, 2–3× per week, for six weeks. The pairing targets cellular energy and collagen biology simultaneously without pathway overlap. Document skin, hair, recovery, and sleep observations weekly to anchor attribution.

Weeks 7–10: NAD+ + Epitalon pulse (telomere focus)

Continue NAD+. Wash out GHK-Cu for four weeks. Beginning at week seven, run Epitalon pulse dosing at 5–10 mg subcutaneously for ten consecutive days, then twenty days off. This is the most structurally distinct phase — pulse-dosed rather than continuous — and it gives clean attribution for any biomarker changes that follow.

Weeks 11–18: NAD+ + BPC-157 (gut and vascular focus)

Continue NAD+. After the Epitalon pulse cycle completes, introduce BPC-157 at 250–500 mcg, 1–2× per day, subcutaneously, for six to eight weeks. The natural endpoint for this block is a four-week BPC-157 washout. Athletes subject to drug testing should not include this block; BPC-157 is WADA-prohibited.

Week 19+: NAD+ continuous, peptide washout

Hold NAD+ as the only active compound for at least four weeks. Re-baseline bloodwork, sleep metrics, recovery, and subjective markers. Decide with your prescriber whether to re-enter a new peptide cycle or remain on NAD+ alone. This washout is the structural feature that distinguishes a research-protocol approach from open-ended stacking.

Finding a provider who can actually prescribe these compounds

The practical barrier to a NAD+ + peptide stack is not the science; it is finding a licensed prescriber able and willing to write for the relevant compounded preparations. Most large telehealth platforms restrict themselves to NAD+ alone. A smaller number operate with broader compounding partnerships, and only a few will touch Epitalon at all.

CareBarRx and similar broad-spectrum telehealth

CareBarRx-style telehealth platforms with broad 503A and 503B compounding partnerships are the most likely on-ramps for patients who want NAD+ co-prescribed with adjunct compounds under licensed-clinician supervision. The model is consultation-led: a clinician reviews medical history, orders baseline labs, and writes for a compounded preparation that is dispensed by a partner pharmacy. This is not a “buy peptides direct” channel — it is a prescribing relationship, which is the only legitimate pathway for any injectable peptide.

See the CareBarRx provider profile

BodyBuilding Health and the NAD+-focused alternative

For readers whose interest is NAD+ rather than the full peptide stack, narrower NAD+-and-B-vitamin focused telehealth such as BodyBuilding Health is a more focused option. The peptide breadth is smaller, but the NAD+ protocols are well-defined and the patient-onboarding experience tends to be simpler. If you are not sure whether you want to layer peptides at all, starting with a NAD+-only provider and adding complexity later is a defensible sequence.

State-by-state legality issues

Compounded preparations are regulated under federal law (FDCA 503A/503B) and state pharmacy boards. Some compounding pharmacies decline Epitalon entirely; others have narrower formularies for BPC-157 or GHK-Cu. Telehealth licensure also varies state-by-state, so a provider available in one state may not be available in another. Before pursuing a stack, confirm three things with your prospective provider: which compounds they actually prescribe, which compounding pharmacy they partner with, and whether they are licensed in your state. Our compare top NAD+ providers tool covers the NAD+ subset of these questions.

Safety and what to monitor

Baseline and follow-up bloodwork are the single highest-leverage safety practice for any longevity stack. A conservative panel includes a comprehensive metabolic panel, complete blood count, lipid panel, fasting glucose and insulin, HbA1c, hsCRP, ferritin, vitamin D, B12 and folate, and a thyroid panel. For NAD+ protocols, whole-blood NAD+ level (if your provider offers it) provides a direct measure of precursor effect. For copper-binding compounds like GHK-Cu, ceruloplasmin and copper levels are reasonable additions over longer cycles. For Epitalon, melatonin and sleep tracking are softer but useful proxies.

Injection-site reactions, transient fatigue, headache, and sleep changes are the most commonly reported subjective effects across the three peptides. Any of these warrant a pause and a check-in with your prescriber. Stop and seek medical attention for signs of allergic reaction, severe injection-site inflammation, or any cardiovascular symptoms. None of these compounds should be combined with active oncology treatment without explicit oncologist oversight; in particular, the telomerase and angiogenesis pathways touched by Epitalon and BPC-157 are exactly the pathways oncologists work to suppress, so co-administration is not appropriate.

Frequently Asked Questions

Is it safe to stack NAD+ with peptides like BPC-157 or GHK-Cu?

There is no large human RCT testing this combination, so any answer is partial. The mechanistic case is reasonable because NAD+ and the peptides act on non-overlapping pathways. The practical answer is that safety depends entirely on supervision: a licensed prescriber reviewing your medical history, ordering baseline labs, supervising cycling, and adjusting for side effects materially changes the risk profile compared to self-administered stacks from research-chemical vendors. The conservative position is — if you are going to do this at all — do it through a clinician, one compound at a time, with cycling discipline and bloodwork follow-up.

Are GHK-Cu, BPC-157, and Epitalon FDA-approved?

No. None of the three are FDA-approved for any clinical injection indication. They are categorized as research compounds. Topical cosmetic GHK-Cu, regulated as a cosmetic rather than a drug, is a separate category and is broadly legal to sell and use. The lack of FDA approval is the single most important fact to internalize before considering any of these compounds, and it is the reason a licensed prescriber, not a research-chemical vendor, is the appropriate intermediary.

What is the difference between research compounds and clinical treatments?

A clinical treatment has been through randomized controlled trials at sufficient scale to satisfy a regulator, has a labeled indication, an approved dose, a manufacturer-tested formulation, and a known safety profile. A research compound has some combination of preclinical data, small human trials, and mechanistic plausibility, but does not yet meet the regulatory standard for a labeled indication. Research compounds can still be prescribed in some contexts through compounding pharmacies, but the patient and the prescriber are operating in a different evidence landscape and should understand that explicitly.

Why is BPC-157 banned by WADA?

The World Anti-Doping Agency added BPC-157 to its prohibited list because its preclinical evidence base — particularly the angiogenesis and tissue-repair signals — suggests a plausible performance and recovery benefit, even in the absence of large human trials. The WADA standard is precautionary: a substance can be prohibited if it has the potential to enhance performance, regardless of whether the FDA has approved it. Any athlete subject to testing should treat BPC-157 as off-limits.

Can I get a prescription for these peptides via telehealth?

Sometimes, depending on the provider, the compound, your state, and the compounding pharmacy. A small number of broad-spectrum telehealth platforms with compounding partnerships will prescribe GHK-Cu and BPC-157 under clinician supervision. Epitalon is much less commonly prescribed, and many compounding pharmacies decline it. Most NAD+-focused telehealth platforms will not prescribe peptides at all. Before pursuing a stack, ask the provider specifically which compounds they will and will not write for in your state.

How long should I cycle Epitalon?

The most commonly reported Epitalon protocol from the Khavinson research literature is a ten-day pulse of 5–10 mg per injection, followed by twenty days off, repeated as appropriate — or a maintenance variant of ten days once per quarter. Pulse dosing is the structural feature that distinguishes Epitalon from GHK-Cu and BPC-157 cycling. The specific cadence should be set by your prescriber based on your goals, baseline labs, and tolerance, not by a forum protocol.

Should I take NAD+ continuously or cycle it like the peptides?

NAD+ in oral precursor or subcutaneous form is most commonly run continuously rather than cycled, because it acts as a baseline coenzyme rather than a pulsed intervention. The peptides are cycled because their dose-response and tolerance profiles favor on-off cadence and because cycling preserves attribution when stacking. Some prescribers do build in a periodic NAD+ break to re-baseline; that is a clinician-level decision rather than a default protocol.

What is the maximum number of peptides I can safely stack?

Our research-protocol position is no more than three active compounds at once, including NAD+ as the baseline. Beyond three, attribution collapses — if a benefit or a side effect appears, you cannot identify which compound is responsible. Consumer longevity content frequently recommends five to seven concurrent compounds; that is a marketing posture, not a research posture. Cycling one peptide at a time on top of NAD+ is the more defensible structure.

Is topical GHK-Cu the same as injectable GHK-Cu?

The molecule is the same, but the regulatory category, the dose, and the systemic exposure are different. Topical GHK-Cu at 1–2% in a serum is regulated as a cosmetic, delivers small amounts through skin, and has a long consumer track record for skin and hair applications. Subcutaneous injectable GHK-Cu at 1–5 mg per injection delivers a systemic dose and is a research compound, not an approved drug. Conflating the two is the most common mistake in consumer peptide content.

What does the 2026 research actually show about these stacks?

As of 2026, there is no published randomized controlled trial of the full NAD+ + GHK-Cu + BPC-157 + Epitalon stack in humans. NAD+ precursor RCTs (2024–2025) show reliable elevation of NAD+ levels and consistent safety signals, with mixed functional outcomes. Individual-peptide evidence remains predominantly preclinical, with the Khavinson Epitalon trials as the principal exception. Treat the stack as a research-context protocol, not as a proven longevity regimen.

Should I get bloodwork before starting a longevity stack?

Yes. A baseline blood panel is the single highest-leverage safety practice for any longevity protocol. A reasonable starting panel includes a comprehensive metabolic panel, complete blood count, lipid panel, fasting glucose and insulin, HbA1c, hsCRP, ferritin, vitamin D, B12, folate, and thyroid markers. Re-test at the end of each peptide cycle. Without baseline labs, you have no way to interpret subjective changes or to identify drift in metabolic markers that could indicate an unwanted effect.

Where can I find a licensed prescriber for NAD+ and longevity peptides?

Broad-spectrum compounding telehealth platforms are the most accessible on-ramp for patients who want NAD+ co-prescribed with adjunct peptides. Our review of CareBarRx covers a platform with broader compounding partnerships than typical NAD+-only telehealth, and our compare top NAD+ providers tool helps narrow the NAD+-first options. Whichever provider you choose, confirm which compounds they actually prescribe in your state before committing.

Sources

• Yoshino J, Baur JA, Imai S. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism.
• Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 2023.
• Brenner C. Nicotinamide Riboside: The Search for a Robust Biomarker of Effect. Nature Communications, multiple years.
• Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018.
• Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy. Current Pharmaceutical Design, multiple years.
• Khavinson VK, et al. Peptide Epitalon as a Geroprotector: Long-Term Studies in Elderly Patients. Bulletin of Experimental Biology and Medicine, multiple years.
• World Anti-Doping Agency. The Prohibited List (current edition). wada-ama.org/en/prohibited-list.
• U.S. Food & Drug Administration. Compounding and the FDA: Questions and Answers (503A/503B framework).